Page
%P
-
Article
Open Access17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia and the anti-CD20 monoclonal antibody, rituximab, represents the therapeutic gold standard for more than 2 decades in this pathology, when...
-
Article
Open AccessSTIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia
Dysregulation in calcium (Ca2+) signaling is a hallmark of chronic lymphocytic leukemia (CLL). While the role of the B cell receptor (BCR) Ca2+ pathway has been associated with disease progression, the importance...